Lunning MA, Wang HL, Hu ZH, Locke FL, et al. Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy. Am J Hematol 2024 Mar 19. doi: 10.1002/ajh.27283.
PMID: 38504387